Rating History for Prelude Therapeutics (PRLD) by Goldman Sachs
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 5/15/2026 | Corinne Johnson | New Coverage | Early-Stage Biotech (N/A) |
N/A (N/A) |
4.47 (3.83) |
-14.32% | Details |
 |
|||||||
